Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 18/20 | 0.58 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512291 | 0.92 | KIF11 (0.58) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4493602 | 0.92 | KIF11 (0.61) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4488835 | 0.92 | KIF11 (0.66) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4508702 | 0.91 | KIF11 (0.64) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4499294 | 0.91 | KIF11 (0.60) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4512645 | 0.91 | KIF11 (0.53) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4497720 | 0.90 | KIF11 (0.58) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4487063 | 0.90 | KIF11 (0.64) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4493021 | 0.88 | KIF11 (0.56) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4493637 | 0.88 | KIF11 (0.44) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476743-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2009-01-13 | — | — | US | claimed |
| US-7476743-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| EP-1558588-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060189671-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-08-24 | — | — | US | disclosed |
| EP-1558588-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004032840-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189671-A1 | Compounds, compositions, and methods | TK1, TK2, TYMP | KIF11 801/4885MAP1LC3B 1697/4885CYP3A4 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.